| James R. Seibold, M.D. | |||||||
| Chair of ISN Medical Advisory Board | |||||||
He had been on the faculty of UMDNJ from 1980-2004 where he had served as Chief of the Division of Rheumatology, Director of the Clinical Research Center and as the W.H. Conzen Chair of Clinical Pharmacology. In July 2004, he became Professor and Director of the University of Michigan Scleroderma Program. Author of more than 300 scientific publications, he is considered a world thought leader in scleroderma, Raynaud's phenomenon and interventional research in the rheumatologic diseases. He has received multiple awards from arthritis and scleroderma patient organizations and appears on virtually every listing of "Best Doctors".
Dr. Seibold is currently the President of the Scleroderma Clinical Trials Consortium - a key partner with the ISN in scleroderma clinical research efforts. (See ISN/SCTC Research Fund). Dr. Seibold is also a Fellow of the American College of Physicians and a Fellow of the American College of Rheumatology. James R. Seibold, M.D. |
|||||||
| Related Links | |||||||
| Voices of Scleroderma Volume 3: Just Released! | |||||||
Voices
of Scleroderma Volume 3 has
just been released, with 100 more new patient and caregiver
stories! Contributing professionals include Dr.
Marco Matucci-Cerinic and Dr.
Irene Miniati (on Systemic Scleroderma), Dr. Fernanda
Falcini (on Juvenile Scleroderma), Dr.
Tafazzul e-Haque Mahmud, Dr. Laszlo Czirjak (on Scleroderma-Like
Disorders), Dr.
James Seibold, Francisco
Castellanos, and Carol
Langenfeld. Posted 01-24-06. |
|||||||
| Scleroderma Lung Disease. The strategy in scleroderma lung disease when disease extent is mild on high-resolution computerized tomography (HRCT) is observation. To determine who deserves procrastination and careful follow-up (limited Interstitial Lung Diseases (ILD)) and who requires therapy (extensive ILD) is a timely goal. Red Orbit. 06/03/08. (Also see: Pulmonary Involvement) | |||||||
| Sitaxsentan, a Selective Endothelin-A Receptor Antagonist, Improves Exercise Capacity in PAH Associated with CTD. Sitaxsentan 100 mg improves the 6-minute walk diagnostic in patients with PAH-CTD with a low incidence of abnormal liver function tests. J. R. Seibold. SAT0233 EULAR 2006. (Also see: Pulmonary Hypertension) | |||||||
|




Dr.
Seibold is Professor of Internal Medicine and Director of
the University of Michigan Scleroderma Program in Ann Arbor,
Michigan, USA.
Voices
of Scleroderma Volume 3
4,
Scleroderma Care and Research Journal: Winter 2004/2005.
3,
Scleroderma Care and Research Journal: Spring 2004.
2,
Scleroderma Care and Research Journal (PDF)
1,
Scleroderma Care and Research Journal (PDF)